The Abbott Nutrition factory linked to the infant formula shortage has reached an agreement to resume operations within two weeks, according to the United States Food and Drug Administration.
Abbott entered into a consent decree with the FDA on Monday, which, if approved by the court, outlines the steps the company must take to resume production at the Michigan plant.
It is the largest infant formula manufacturing plant in the United States and has been closed since February after complaints of bacterial infection in four hospitalized infants, two of whom died.
Parents are now struggling to find infant formula across the country and shelves are empty due to a combination of product recalls, supply chain issues and labor shortages.
The company said there was no connection to its products and it could restart production within two weeks, but it would take “six to eight weeks” for this product to hit its shelves.
“Our number one priority is to provide infants and families with the high-quality formulas they need, and this is a major step towards reopening our Sturgis plant so that we can alleviate the shortage of formulas at the nationwide,” said Robert B Ford, President and CEO. Abbott officer.
“We know millions of parents and caregivers depend on us and we are deeply sorry that our voluntary recall has exacerbated the nationwide formula shortage.”
FDA chief Dr. Robert Califf said Monday he doesn’t expect the shortage to last until the end of the year.
“We don’t expect it to last until the end of the year, far from it. We are taking a number of actions, including calling on all manufacturers to step up,” he said.
The Independent Gt